.jpeg)
Is ruxolitinib cream included in domestic medical insurance? Is it reimbursable and what are the conditions for medical insurance reimbursement?
Ruxolitinib cream (Opzelura) has not yet been approved for marketing in China. Therefore, patients cannot purchase the drug through regular domestic channels. Since it is not listed in the domestic market, it is not included in China's medical insurance system. This means that patients need to purchase the drug themselves through overseas channels, usually through international drug platforms or purchasing agents.
In foreign markets, the original version of ruxolitinib cream is produced by Incyte and sells for about 10,000 yuan. In comparison, the imitation version produced by Bangladesh Yaopin International Company is more affordable, with a tube selling for about five to six hundred yuan. Although generic drugs have obvious advantages in price, their drug ingredients are basically the same as the original drugs, so they are a viable option for patients with limited financial conditions.
In short, ruxolitinib cream still needs to be purchased through foreign channels and cannot be reimbursed by domestic medical insurance. Patients need to carefully select the source of drugs when purchasing, ensure the legality and safety of the drugs, and budget the relevant costs, especially the price difference between original drugs and generic drugs.
Reference: https://www.opzelura.com/
[ 免责声明 ] 本页面内容来自公开渠道（如FDA官网、Drugs官网、原研药厂官网等），仅供持有医疗专业资质的人员用于医学药学研究参考，不构成任何治疗建议或药品推荐。所涉药品可能未在中国大陆获批上市，不适用于中国境内销售和使用。如需治疗，请咨询正规医疗机构。本站不提供药品销售或代购服务。
